First line EGFR-TKI for advanced non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2010.04.020
- VernacularTitle:EGFR-TKI一线治疗晚期非小细胞肺癌研究进展
- Author:
Yun FAN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Receptor,epidermal growth factor;
Protein tyrosine kinase
- From:
Journal of International Oncology
2010;37(4):299-302
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor ( EGFR)-small molecule tyrosine kinase inhibitor (TKI) has become the focus of clinical trials for first-line treatment of advanced non-small cell lung cancer ( NSCLC). Though TKI and concurrent chemotherapy show no advantage for survival, the use of TKI in combination with chemotherapy ( sequenced or maintenance) prolongs progression-free survival. In those patients with EGFR mutation, TKI as monotherapy in first-line setting has a significant effect on progression - free survival compared with chemotherapy. These data shows that EGFR mutation is effective predictor for TKI treatment.
